Given that maladaptive fibrosis is a principal determinant of heart failure following myocardial infarction, targeting the UCK2/UCKL1-TRIM21 regulatory node offers a promising therapeutic strategy to arrest fibrogenesis and improve clinical outcomes in ischemic heart disease. Here, UCKL1 is linked to coronary artery disorder.